Home > Boards > US OTC > Medical - Equipment > StatSure Diagnostic Systems (SSUR)

Improving Risk/Reward Ratio and Growth Outlook

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
LilKahuna Member Profile
 
Followed By 247
Posts 20,546
Boards Moderated 1
Alias Born 10/03/04
160x600 placeholder
LilKahuna   Tuesday, 11/06/07 09:56:11 AM
Re: Ubertino post# 95
Post # of 145 
Improving Risk/Reward Ratio and Growth Outlook

[I especially like this part of the report. Thanks for posting that, nanopatent! --Doc FG]

Scimitar maintains a “BUY” ranking on SSUR.OB and has upgraded the
modeled valuation to $1.66 from $1.25 based on the impact of receipt of the
CLIA Waiver. The revenue impact of this “waiver” affects the risk/reward
scenario due primarily to SSUR.OB’s value drivers: a virtual operating mode
(manufacturing and marketing are outsourced), modest executive infrastructure,
the financial (margin) model (reflected by the terms of the “three-way deal); the
results of which provides for a high percentage of revenues to drop to the
bottom line. These value-drivers are transparent, simple and strong
determinants of SSUR.OB’s business and operating model.


http://www.scimitarequity.com/research/SSUR.OB_Mid-Quarter_Review.pdf

doc.feelgoode@yahoo.com

"It ain't what they call you, it's what you answer to." --WC Fields


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences